ESMO 2025 Conference Review focus on Breast Cancer

In this edition:

DESTINY-Breast05: post-neoadjuvant T-DXd vs. T-DM1 in high-risk, HER2+ early breast cancer
DESTINY-Breast11: neoadjuvant T-DXd-THP versus ddAC-THP for high-risk, HER2+ early breast cancer
monarchE: updated results of adjuvant abemaciclib + endocrine therapy in HR+, HER2–, high-risk early breast cancer
NATALEE: 5-year outcomes of ribociclib + NSAI in stage I/III, HR+, HER2− early breast cancer
evERA BD: second-line giredestrant + everolimus in ER+, HER2– advanced breast cancer
VIKTORIA-1: second-line gedatolisib + fulvestrant ± palbociclib in HR+, HER2–, PIK3CA wild-type advanced breast cancer
POSITIVE: updated 5-year results
REaCT-Hold BMA: de-escalation of BMAs after ≥2 years in breast/prostate cancer with bone metastases
ASCENT-03: sacituzumab govitecan in advanced TNBC ineligible for PD-(L)1 inhibitors
TROPION-Breast02: Dato-DXd vs. chemotherapy in metastatic TNBC ineligible for immunotherapy